Potential oral therapy in MS

Article

Oral resveratrol SRT501 significantly lowers neuronal damage, in a model of multiple scelrosis (MS).

A study published in the Journal of Neuro-Ophthalmology claims that oral resveratrol SRT501 significantly lowers neuronal damage, in a model of multiple scelrosis (MS).

It was found that the pharmaceutical grade formulation of SRT501 activated the NAD+ dependent deacetylase SIRT1 and encourages mitochondrial function.

Dr Kenneth S. Shindler, et al., Penn Presbyterian Medical Center, Philladelphia, USA, looked at the effect oral therapy SRT501, a pharmaceutical grade formulation of resveratrol, has on neuronal loss during relapse-remitting experimental autoimmune ancephalomyelititis (EAE). The therapy resveratrol is known to activate the NAD+ dependent deacetylase, SIRTI, which encourages mitochondrial function.

It was found that SRT501 prevented neuronal loss in optic neuritis and suppressed neurological dysfunction during EAE remission. The results also revealed that a SIRTI inhibitor, sirtinol, reduced the neuroprotective effects of SRT501 and other SIRTI activators gave similar results to SRT501.

It was concluded that resveratrol is effective in lowering neuronal damage in EAE through activation of SIRTI so therapies activating this deacetylase have potential as oral therapies in MS.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.